Tanya Lewis

Insider Reports History

Location
Minneapolis, MN
Signature
/s/ Scott Kellen, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Tanya Lewis:

Company Role Class Num Shares Value Price $ Report Date Ownership
Replimune Group, Inc. Chief Dev. Op. Officer Common Stock 135,293 $1,477,400 $10.92 13 Jun 2023 Direct
DiaMedica Therapeutics Inc. Director Voting Common Shares, no par value per share 0 $0 $3.69 01 Jun 2025 Direct
DiaMedica Therapeutics Inc. Director Voting Common Shares, no par value per share 0 $0 $2.80 01 Jun 2024 Direct
DiaMedica Therapeutics Inc. Director Stock Option (right to buy) 32,162 01 Jun 2025 Direct

Insider Reports Filed by Tanya Lewis

Symbol Company Period Transactions Value $ Form Type Role Filing Time
DMAC DiaMedica Therapeutics Inc. 01 Jun 2025 1 $0 4 Director 03 Jun 2025, 16:17
DMAC DiaMedica Therapeutics Inc. 01 Jun 2024 1 $0 4 Director 03 Jun 2024, 16:14
REPL Replimune Group, Inc. 13 Jun 2023 2 -$309,395 4 Chief Dev. Op. Officer 15 Jun 2023, 21:01
DMAC DiaMedica Therapeutics Inc. 01 Jun 2023 1 $0 4 Director 02 Jun 2023, 16:13
REPL Replimune Group, Inc. 16 May 2023 1 -$220,336 4 Chief Dev. Op. Officer 18 May 2023, 20:34
REPL Replimune Group, Inc. 01 Apr 2023 2 $0 4 Chief Dev. Op. Officer 04 Apr 2023, 20:01
DMAC DiaMedica Therapeutics Inc. 01 Mar 2023 1 $0 4 Director 06 Mar 2023, 16:14
DMAC DiaMedica Therapeutics Inc. 01 Mar 2023 0 $0 3 Director 06 Mar 2023, 16:06
REPL Replimune Group, Inc. 16 May 2022 1 -$79,851 4 Chief Dev. Op Officer 18 May 2022, 19:02
REPL Replimune Group, Inc. 01 Apr 2022 2 $0 4 Chief Dev.Op Off 05 Apr 2022, 16:15
REPL Replimune Group, Inc. 10 May 2021 2 $0 4 Chief Dev. Oper. Off. 11 May 2021, 21:01